Afatinib plus Bevacizumab Combination after osimertinib failure for aDvanced EGFR-mutant non-small cell lung cancer: a multicenter prospective single arm phase II study (ABCD-study)
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000030545
- Lead Sponsor
- Hanshin Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 26
Not provided
1) Interstitial lung disease or pulmonary fibrosis 2) Symptomatic central nervous system metastases 3) History of severe allergic reaction to drugs 4) Severe infection or comorbidities 5) Massive or uncontrolled pleural, abdominal, or cardiac effusion 6) Clinically significant arythmia, angina, or heart failure 7) Uncontrolled hypertension 8) Uncntrolled diabetes 9) Active double cancers 10) Hitologically dominant of squanous carcinoma 11) Severe phycological disease 12) Massive hemoptysis 13) Gastrointestinal perfolation within 1 year 14) Incurable bone fracture 15) Planning major surgery during trial 16) Bleeding tendency 17) Uncontrolled thrombosis 18) Receipt of EGFR-TKIs other than Osimertinib or immunotherapy 19) Pregnancy 20) Patients whom doctos in charge judge unproper
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method